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Viral vectors have become very popular to overexpress or downregulate proteins of
interest in different cell types. They conveniently allow the precise targeting of well-
defined tissue areas, which is particularly useful in complex organs like the brain. In
theory, each vector should have its own cell specificity that can be obtained by using
different strategies (e.g., using a cell-specific promoter). For the moment, there is few
vectors that have been developed to alternatively target, using the same capsid, neurons
and astrocytes in the central nervous system. There is even fewer examples of adeno-
associated viral vectors able to efficiently transduce cells both in vitro and in vivo. The
development of viral vectors allowing the cell-specific downregulation of a protein in
cultured cells of the central nervous system as well as in vivo within a large brain area
would be highly desirable to address several important questions in neurobiology. Here
we report that the use of the AAV2/DJ viral vector associated to an hybrid CMV/chicken
β-actin promoter (CBA) or to a modified form of the glial fibrillary acidic protein promoter
(G1B3) allows a specific transduction of neurons or astrocytes in more than half of
the barrel field within the rat somatosensory cortex. Moreover, the use of the miR30E-
shRNA technology led to an efficient downregulation of two proteins of interest related
to metabolism both in vitro and in vivo. Our results demonstrate that it is possible to
downregulate the expression of different protein isoforms in a cell-specific manner using
a common serotype. It is proposed that such an approach could be extended to other
cell types and used to target several proteins of interest within the same brain area.
Keywords: AAV2/DJ, shRNA, neurons, astrocytes, MCT2, MCT4, miR30E, barrel cortex
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INTRODUCTION
Viral vectors are used as tools to spatially and temporally regulate
the expression of proteins in a wide range of cell types, including
brain cells (Davidson et al., 2000; Burger et al., 2004). Adeno-
associated viral vectors (AAVs) are one of the most commonly
used for several reasons. AAVs are single-stranded DNA viruses
with a short DNA length, about 4.7 kb (Hoggan et al., 1966).
Because of their inability to replicate in the absence of a
helper virus, e.g., Adenovirus or Herpesvirus, and because of
their episomal form in the nucleus, working with AAVs in the
laboratory is considered as safe (Dismuke et al., 2013). Moreover,
this virus is not associated with any human disease (Flotte
and Berns, 2005). It was shown that over 80% of the human
population has been infected with the AAV2 (Calcedo et al.,
2009). Because of their small size (about 20 nm), AAVs largely
diffuse in the rodent brain and are widely used for in vivo brain
studies (Aschauer et al., 2013). Unfortunately, most of the AAVs
have a low efficiency in vitro (Ellis et al., 2013). This downside
forced researchers in the past to choose different serotypes or
even different viral vectors for in vitro and in vivo studies,
introducing an unavoidable bias in their study.
Few years ago, the AAV2/DJ serotype was developed (Grimm
et al., 2008). This serotype was created from the shuffling
of capsids between eight existing serotypes (AAV2, 4, 5, 8,
9, Avian, Caprine, and Bovine). It was shown in vitro that
the AAV2/DJ outperforms the other serotypes in terms of
transduction efficiency in vitro (above 1,000 times depending on
the cell line studied). It was also shown that the AAV2/DJ remains
highly efficient in vivo like the other AAVs (Holehonnur et al.,
2014; de Solis et al., 2017).
The ability to transduce different cell types is primarily
determined by the AAV capsid proteins. Each AAV serotype
has its own tropism, i.e., its own specificity for a particular cell
type (Daya and Berns, 2008). Most AAVs have a prominent
neuronal tropism (e.g., AAV2, AAV5) except AAV4 that targets
predominantly astrocytes (Liu et al., 2005). Several years ago,
it was shown that the capsid is not the only parameter that
determines the cell specificity of a viral vector. Changing
the promoter can modify the cell-specific expression of the
transduced sequence, e.g., the use of an astrocyte-specific
promoter can change the cell-specific expression from neuronal
to astrocytic (Brenner et al., 1994).
Adeno-associated viral vectors are widely used to overexpress
small proteins in a specific cell type. Fewer studies were
conducted using AAVs to downregulate the expression of a
protein in a cell-specific manner. Indeed, the AAV DNA length
(4.7 kb) prevents the use of efficient knockout strategies such
as the CRISPR-Cas9 system. The transgene size is usually too
large, over 3 kb (Jiang and Doudna, 2017). The other commonly
used strategy for protein expression downregulation is RNA
interference, a post-transcriptional gene regulation mechanism
that uses short hairpin RNAs (shRNAs) complementary to the
targeted mRNA that will bind to it and favor its degradation
(Rao et al., 2009). The incorporation of shRNAs into endogenous
microRNA contexts is offering the possibility to use cell-type
specific polymerase II promoter. Furthermore, Fellmann et al.
(2013) showed that embedding the shRNA sequence in a miR30E
backbone (miR30E-shRNA) allows the cell to recognize the
sequence as its own and process it in a controlled manner,
increasing the yield of downregulation.
The use of a highly efficient downregulation tool targeting
different cell types could permit to conduct studies targeting
different isoforms of the same protein family expressed by
different cell types within the same tissue. The association of
the miR30E-shRNA with the AAV2/DJ represents an interesting
strategy to target different isoforms in different cell types in
the same tissue. Our goal was to combine those two elements
to downregulate, in vitro and in vivo, the expression of two
monocarboxylate transporter isoforms (MCTs). These proteins
are key players for the astrocyte-neuron lactate shuttle (ANLS),
a mechanism purported to play a central role in neuroenergetics
(Pellerin and Magistretti, 1994). MCTs form a small group
of proton-linked carriers of energy substrates, which includes
lactate, pyruvate and ketone bodies. In the central nervous
system, MCT2 is predominantly expressed by neurons whereas
MCT4 is found solely on astrocytes (Halestrap and Price, 1999).
To achieve our goal, we developed AAV2/DJ viral vectors with
two different promoters specific for neurons or astrocytes, and
injected them in the barrel field of the rat primary somatosensory
cortex (S1BF). We verified that, as expected, the chicken β-actin
promoter (CBA, 0.8 kbp; Wang et al., 2003; Gray et al., 2011)
led to a neuronal expression of the reporter protein and the
modified form of the glial fibrillary acidic protein promoter G1B3
(Merienne et al., 2017) led to an astrocytic expression. Then,
derived vectors harboring a specific shRNA sequence against
one of the two MCT isoforms were tested in vitro and in vivo
for their capacity to selectively downregulate the expression
of MCT2 and MCT4.
MATERIALS AND METHODS
Reference of materials and resources can be found in
Supplementary Table 1.
Animals
Adult Wistar rats (over 7 weeks old, males only for in vivo
experiments and pregnant females for in vitro experiments,
Janvier Laboratories, RRID:RGD_13508588) were used under the
protocol approved by the Swiss “Service de la Consommation
et des Affaires Vétérinaires (SCAV, authorization n◦3101.1) in
accordance with Swiss animal welfare laws. They were housed by
two and maintained on a 12 h light/dark cycle. Food and water
were provided ad libitum throughout the experiment. Littermates
of the same sex were randomly assigned to experimental groups.
Plasmids Cloning
Plasmids from Geneart (Supplementary Table 1, Recombinant
DNA, pMK) were cloned into a pENTR (pENTR-mCherry-
miR30E-shHTT6) kindly provided by Pr. Nicole Déglon
(Supplementary Table 1, Recombinant DNA, pENTR). This
pENTR already contained the reporter gene (mCherry). Then,
Gateway LR Clonase reaction was performed to insert the pENTR
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fragment mCherry-miR30E-miR30E-shRNA into destination
vectors pAAV2ss-CBA-RFA-WPRE-bGH or pAAV2-G1B3-
RFA-WPRE-bGH. Final products (Supplementary Table 1,
Recombinant DNA, pAAV2ss) were then used to produce AAVs.
The CBA promoter is a hybrid promoter corresponding to
the chicken beta actin promoter with the enhancer sequence
of the cytomegalovirus (Wang et al., 2003; Gray et al., 2011).
The G1B3 promoter is a modified form of the GfaABC1D
promoter, derived from the Glial Fibrillary Acidic Protein
(GFAP) (Merienne et al., 2017). More precisely, three copies of
the “B” enhancer sequence from Gfa2(b)3 (De Leeuw et al., 2006)
have been cloned in the GfaABC1D promoter (Lee et al., 2008)
to generate GfaABC1D(B3) (hereafter called G1B3; Merienne
et al., 2017). The combination of those modifications led to a
greater expression level and a more astrocyte-specific expression.
The ITR (Inverted Terminal Sequence) allows the formation
of episomally stable concatemers. The WPRE (Woodchuck
hepatitis virus Post-Regulational Element) sequence enhances
the expression of the transgene. The bGH (bovine Growth
Hormone) sequence promotes polyadenylation and termination
of the transgene.
AAV Production
Adeno-associated viral vectors were produced in HEK293T
cells, transfected with pHelper, pAAV-DJ_Rep_Cap and pAAV2-
transgene using the calcium phosphate precipitation method.
Cells and supernatant were harvested 72 h post-transfection
and centrifuged for 10 min at 300 g at 4◦C. Supernatant
and cell pellet were processed in parallel. Supernatant was
incubated in 8% Polyethylene Glycol, 2.5 M NaCl for 2 h
at 4◦C. Pellets were pooled and incubated with lysis buffer
(0.15 M NaCl, 50 mM Tris–HCl, pH 8.5) for three cycles
of freeze/thaw steps (30 min in dry ice/ethanol followed
by 30 min at 37◦C). The PEG-precipitated supernatant was
centrifuged at 4,000 g for 20 min at 4◦C and the pellet was
stored. The lysate was added to the pellet and incubated at
37◦C for 1 h. The cellular lysate was treated with Benzonase
(50 units/mL) in 1 M MgCl2 for 30 min at 37◦C. Then the
lysate was centrifuged at 4,000 g for 20 min at 4◦C. AAVs were
separated using iodixanol gradient centrifugation at 59,000 rpm
(70Ti rotor, Beckman-Coulter) for 90 min at 20◦C. Phase
containing AAVs was harvested and loaded on an Amicon
Ultra-15PL 100 column with 0.001% Pluronic F68 D-PBS for
iodixanol cleaning and viral particles concentration. Tubes were
first centrifuged at 4,000 g at 4◦C until the whole solution
has passed through the column. AAVs were resuspended in
200 µL 0.001% Pluronic F68 D-PBS. The viral genome content
(vg/mL) of each AAV2/DJ was assessed by Taqman R©qPCR with
primers recognizing Inverted Terminal Repeats of AAV2 viral
genome (Supplementary Table 1, Oligonucleotides). AAV2/DJ
was stored at−80◦C until use.
Stereotaxic Surgery
Surgeries were performed on 7 weeks old animals. Animals
were randomly assigned to experimental groups. Animals were
anesthetized with isoflurane (5% for the induction and 3%
to maintain the anesthesia). AAVs or PBS were injected
in one site/hemisphere (S1BF: Anteroposterior = −2,3 mm;
Mediolateral = ±5 mm; Dorsoventral = −3 mm). Viral vectors
were injected with 34 G steel cannula fixed on a cannula holder
and linked to a 10 µL Hamilton syringe and an infusion pump.
For each site, 4 µL of viral vector were injected at 0.2 µL/min.
Cannulas were left in the brain for 5 min after the injection,
and then slowly removed. Skin was closed using 4.0 sterile
suture thread. Sterile NaCl 0.9% solution (1 mL) was delivered
to the rat by intra-peritoneal injection to avoid dehydration
after surgery, and healing cream was applied on the head.
Sugar-taste Paracetamol was delivered to the animal in water
(1 g/cage for rats) during 72 h. Animals were monitored until
complete awakening, and every day during 3 days after the
surgery. All viral vectors were injected at a final concentration
of 1× 108 g/site.
Brain Samples Processing
For brain fixation, animals were anesthetized by lethal i.p.
injection of Pentobarbital (150 mg/kg, 1 mL/kg). Intra-
cardiac perfusion of cold PBS 1× was performed during
1 min (30 mL/min), followed by perfusion of cold fresh
Paraformaldehyde 4% (PFA 4%) solution diluted in 0.15 M of
Na-Phosphate buffer during 10 min (30 mL/min). The brain
was quickly dissected and post-fixed in PFA 4% during 12 h,
followed by cryo-protection in PBS 1×-Sucrose 20% (24 h) and
PBS 1×-Sucrose 30% (24 h). Brains were conserved at –80◦C
until being sectioned at 25 µm with a cryostat.
For RNA and protein extractions, all procedures were
performed under RNAse-free conditions. Rats were slightly
anesthetized using Isoflurane and quickly decapitated. After,
brain was removed and placed in a cold dissection matrix to
prepare 1 mm sections. Barrel cortex area was quickly isolated
and punches were immediately homogenized on ice in 1 mL of
Trizol Reagent and stored at−80◦C until use.
Mixed Primary Cultures of Rat Cortical
Neurons and Astrocytes
The day before dissection, culture wells (6-well plates) were
coated with Poly-L-Ornithine Hydrobromide 15 mg/mL. The
pregnant female was sacrificed (at E17–17.5, days of gestation)
by decapitation. Embryos were extracted and then cortices were
isolated and minced. Minced cortices were then incubated at
37◦C with a papain solution (HBSS with Penicillin-Streptomycin
1×, 1 mM L-cysteine, DNAse I 1,000 U and Papain 200 U) for
30 min. Papain activity was then quenched by 1 mL of FBS.
Cortices were then finely dissociated in culture medium (High
glucose DMEM, B-27 supplement 1×, FBS 10%) by gentle up
and down movements in a sterile Pasteur pipette. The solution
containing the dissociated cells was then centrifuged for 15 min at
1,000 g. Cells were resuspended in culture medium, counted and
plated (200,000 cells per well). A neurons/astrocytes proportion
of about 1:3 was obtained at the end of the culture time (because
of astrocytes proliferation).
The MOI (Multiplicity of Infection) was calculated as the
number of viral particles needed per cell (AAV number/total
number of cells, Ellis et al., 2013). After 5 days of culture,
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the culture medium was changed and cells were infected using
increasing doses of viral vectors (MOI of 500, 2,000, 4,000 and
7,000). To avoid differences in temperature and volume of culture
medium, only 40 µL of diluted vector were added per well.
After 11 days of culture, cells were incubated with 600 µM of
DETA-NONOate, a NO donor, for 16 h. This exposure mimics
the effect of physoxia. Indeed, at 21% of O2, astrocytes do not
express MCT4 (Marcillac et al., 2011). At day 12 in vitro, all cells
were collected using 350 µL of RLT Buffer from the RNeasy mini
kit (Qiagen) and stored at −80◦C until use for mRNA extraction
and in 100 µL of RIPA buffer and stored at −20◦C until use for
protein extraction.
Immunohistochemistry
Primary and secondary antibodies used in this study are
described in the Supplementary Table 1. Free-floating sections
of 25 µm were washed three times (5 min/wash) at RT in
PBS 1×, blocked 1 h in PBS 1× containing 10% Bovine Serum
Albumin Fraction V (BSA) and 0.1% of Triton x-100. Sections
were incubated overnight at 4◦C in PBS 1× containing 5%
BSA, 0.1% Triton x-100 and primary antibodies diluted at
1/500. The following day, sections were washed three times
(5 min/wash) in PBS 1× and incubated 2 h in PBS 1× containing
5% BSA, 0.1% Triton x-100 and secondary antibodies (diluted
at 1/1,000). Sections were finally washed 3 times in PBS 1×,
incubated in Hoechst 33342 trihydrochloride trihydrate solution
(10 µg/mL) during 5 min at RT, washed three times in PBS
1× and mounted on SuperFrost Ultra Plus microscope slide in
Fluoromount medium.
RNA and Protein Extraction
RNA and protein extractions were performed on ice under
RNAse free conditions, with ultrapure sterile RNAse-DNAse-
Protease free water. Extractions from in vivo experiments
were performed according to the Trizol kit recommendations
(mRNA and protein extraction). Extractions from in vitro
experiments were performed according to the RNeasy mini kit
recommendations. At the end, RNAs were finally resuspended
in 22 µL of ultrapure sterile RNAse-DNAse-Protease free water
and stored at−80◦C. RNA concentration and potential chemical
contamination were determined using a Nanodrop 1,000.
Samples with aberrant 280/260 and 260/230 ratio were discarded.
Cells were collected in RIPA buffer. Samples were sonicated 3
times for 5 s at an intensity of 70% and centrifuged at 10,000 g
for 5 min. Supernatants were collected and protein concentration
was measured using a micro BCA assay (see below).
Reverse Transcription and qPCR
Reverse transcription was performed according to the
SuperScript Transcriptase II protocol. 50 µM Random Hexamers
and 10 mM dNTP mix were added to 200 ng of samples. Samples
were incubated for 5 min at 65◦C. Then, First Strand Buffer
5×, 0.1 M DTT and ultrapure DNAse-RNAse free water were
added. Samples were incubated for 2 min at 25◦C. Finally, 200
units of SuperScript Transcriptase II were added and tubes were
incubated in a Thermocycler to perform the reaction (10 min at
25◦C, 50 min at 42◦C and 15 min at 70◦C). At the end, cDNAs
were diluted to obtain a final concentration of 1 ng/L.
Quantitative PCR was performed on 2 ng of cDNA following
the protocol of the SensiFAST SyBr Hi-Rox kit. Samples were
incubated at 95◦C for 3 min then 40 cycles of 3 s at 95◦C
and 20 s at 60◦C. For every experiment, the expression of the
gene of interest was reported to RPS29 (Ribosomal Protein
S29) expression.
Protein Measurement and Western Blot
Protein concentration was evaluated using the Micro
BCA Protein assay kit, according to the manufacturer’s
recommendations. Diluted proteins were mixed with Laemmli
Buffer 4×. Samples and molecular standards (PageRuler) were
loaded on a SDS-PAGE 12% acrylamide gel and then transferred
on a nitrocellulose membrane by semi-dry transfer (Transblot
Turbo). At the end of transfer, membranes were blocked for
1 h, under agitation, at RT with Odyssey Blocking Buffer. Then,
membranes were incubated with the primary antibodies in the
Odyssey Blocking Buffer overnight, at 4◦C, under agitation. The
following day, membranes were washed in PBS-0.1% Triton x-
100 and incubated with secondary antibodies diluted in Odyssey
Blocking Buffer for 2 h, at RT, under agitation. After few washes
in PBS-0.1% Triton x-100, membranes were revealed with the
LI-COR Odyssey device. The expression of the gene of interest
was reported to β-actin expression for in vitro experiments and
to β III-tubulin expression for in vivo experiments.
Image Acquisition and Quantification
Images were obtained using a Zeiss LSM 710 Quasar confocal
microscope. For diffusion analysis, all acquisition parameters
were kept constant between sections for each animal. All analyses
were performed on raw unmodified images. Colocalization
analysis was performed on ImageJ (v1.44 p), using the Plugin
Cell Counter1. To analyze the diffusion of the vector, Tile scans
of 7× 7 were taken on the confocal microscope.
Statistical Analysis
Statistical analyses were performed with GraphPad Prism (v.
7.04). For colocalization analyses and in vivo studies, a Student’s
t-test was applied and results were considered significant when
p < 0.05. Results are presented as mean ± SEM. For in vitro
studies, one-way ANOVA was used followed by a Dunnett’s test
that compares each condition to the non-transduced condition.
RESULTS
AAV2/DJ-based viral vectors have been recently introduced and
need to be further characterized before being popularized as
tools for biological studies, notably in the central nervous system.
Indeed, it has already been tested in the brain to overexpress a
protein as a model of Huntington’s disease (Jang et al., 2018) but
not to downregulate protein isoforms. In order to do so, different
parameters such as their cell-specific transduction and diffusion
in vivo were measured to validate their usefulness.
1Software available on: http://imagej.nih.gov/ij/index.html.
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Large Diffusion in the Rat S1BF Area and
Neuron-Specific Expression of the
Transgene With an AAV2/DJ Viral Vector
Containing a CBA Promoter
A first construct was generated with a control non-coding
sequence (shUNIV) embedded in a miR30E sequence positioned
after a mCherry sequence, both under the control of a CBA
promoter (which was reported to promote a neuronal expression,
Meunier et al., 2016; Figure 1A). The resulting AAV2/DJ-
CBA-mCherry-mir30E-shUNIV viral vector was injected at
a single site in the S1BF area of the rat (stereotaxic
coordinates: anteroposterior =−2.3 mm; mediolateral =±5 mm;
dorsoventral = −3 mm). After 3 weeks, the diffusion of the viral
vector was analyzed using immunofluorescence to amplify the
mCherry signal and enhance its detection, especially in small
neuronal elements such as fine processes. Transduced cell bodies
were found in a large area of S1BF (±0.5 mm around the
needle track along the anteroposterior axis) mainly localized
in layers IV/V/VI (Figure 1B). In addition, many fibers were
also transduced (Figure 1C) and covered a larger area than cell
bodies (±1 mm around the needle track along the anteroposterior
axis). Transduced fibers were found in all cortical layers. If all
transduced cell bodies and fibers are taken into account, the
viral vector has diffused over half of the entire S1BF area. The
cellular specificity of the vector was determined by analyzing
mCherry expression in the two major cell types transduced by
the vector (Figure 1D). Co-localization between NeuN/mCherry
(revealing transduced neurons) and GS/mCherry (revealing
transduced astrocytes) was quantified. The vector preferentially
FIGURE 1 | Large diffusion and neuronal specificity of the AAV2/DJ-CBA-mCherry-miR30E-shUNIV vector within the S1BF area of the rat cerebral cortex.
(A) Schematic representation of the viral vector construction used to target neurons. The mCherry transgene was placed under the control of a CBA promoter. The
shUNIV is a non-coding sequence embedded in a miR30E sequence. (B) Confocal mosaic pictures of the mCherry signal (reporter protein) after immunolabeling of
coronal brain sections taken at 20× magnification showing the diffusion of the viral vector in the cerebral cortex along the anteroposterior axis (upper panels). The
first picture was taken from a section at Bregma –1.40 mm and the last one from a section at Bregma –3.14 mm. On the fourth picture, the position of the different
cortical layers is indicated. Scale bar = 500 µm. The lower panels represent schemes taken from the Paxinos rat atlas (Paxinos and Watson, 1996). Each of the six
schemes corresponds to the bregma level presented in the panel above. The area colored in red corresponds to S1BF, the targeted area. (C) Representative
confocal pictures of the transduced area in a coronal brain section submitted to a co-immunolabeling for mCherry and the neuronal marker NeuN. The right part of
the panel represents a mosaic picture (5 × 5 at 20× magnification) of the transduced area in S1BF. Scale bar = 200 µm. The left part of the panel represents a
portion of the transduced area at 20× magnification. Scale bar = 100 µm. (D) Representative confocal pictures at high magnification (40×) of S1BF 3 weeks after
the injection of the viral vector and submitted to a co-immunolabeling for mCherry, NeuN and GS. The white arrow indicates a typical transduced neuron. Scale
bar = 50 µm. (E) Quantification of the percentage of mCherry-positive/NeuN-positive cells and mCherry-positive/GS-positive cells. Data are presented as
mean ± SEM. Quantification was performed on two to six images per section, six sections per animal, from two animals. Statistical analysis was performed using a
Student’s t-test. ∗∗∗p < 0.001.
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and largely transduced neurons over astrocytes (89.44% ± 0.99
vs. 3.18% ± 0.66, respectively, Figure 1E). Moreover, with the
dose used (see section “Materials and Methods”) and a single
injection, the viral vector was able to transduce 34% of NeuN-
positive neurons within the transduced area.
Large Diffusion in the Rat S1BF Area and
Astrocyte-Specific Expression of the
Transgene With an AAV2/DJ Vector
Containing a G1B3 Promoter
A second construct was made by replacing the CBA promoter
with a modified version of the astrocytic promoter GfaABC1D
(Merienne et al., 2017, Figure 2A). Three copies of the B
enhancer were integrated to improve transgene expression in
astrocytes [GfaABC1D(B3), hereafter called G1B3] (Merienne
et al., 2017). The diffusion of this newly made AAV2/DJ-G1B3-
mCherry-mir30E-shUNIV viral vector was analyzed following
a single injection in the S1BF area of the rat (same stereotaxic
coordinates as for the AAV2/DJ-CBA-mCherry-mir30E-shUNIV
above). Three weeks after the injection, detection of the mCherry
signal was made by performing immunolabeling on brain
sections. Transduced cell bodies were found in a restricted part of
the barrel cortex (±0.2 mm around the needle track). Transduced
cell bodies were found to be mainly localized in layers V/VI
of the barrel cortex (Figure 2B). Many transduced processes
were also visible all around cell bodies (Figure 2C). Transduced
processes were found in a larger area compared to cell bodies
(±1 mm around the needle track along the anteroposterior axis).
All cortical layers exhibited transduced processes. Consequently,
the estimated transduced area covered half of the S1BF. Again, the
cellular specificity of the vector was determined by analyzing the
fluorescent signal found in the two main cell types transduced by
the vector (Figure 2D). Co-localization between NeuN/mCherry
and GS/mCherry was quantified. The vector preferentially and
largely transduced astrocytes over neurons (76.99% ± 1.72 vs.
11.99% ± 1.29, respectively, Figure 2E). With the dose used
(see section “Materials and Methods”) and a single injection,
approximately 70% of GS-positive cortical astrocytes were
transduced by the viral vector within the transduced area.
Efficient Downregulation of Both
Neuronal MCT2 mRNA and Protein
Expression in vitro as Well as in vivo
Using the Same
AAV2/DJ-CBA-mCherry-mir30E-shMCT2
Viral Vector
A viral vector derived from the initial AAV2/DJ-CBA vector was
created in order to target MCT2 in neurons. In addition to the
vector used to characterize the diffusion (used here as control),
one construct was made using a shRNA sequence against MCT2
(shMCT2) embedded in mir30E sequence (Figure 3A). Then,
mixed primary cultures of rat cortical neurons and astrocytes
were transduced with increasing doses of each viral vector named
CBA-shUNIV and CBA-shMCT2 at day 5 in vitro. After 12 days
of culture, both MCT2 mRNA and protein expression levels
were determined. It was found that MCT2 mRNA expression
significantly decreased with CBA-shMCT2 (reaching a decrease
of 62% at the highest dose), while its expression level remained
constant at all doses tested when cells were transduced with CBA-
shUNIV (Figure 3B). At the protein level, both the control and
the targeting vectors caused an initial decrease in expression of
MCT2 at MOI 2,000 although it did not reach significance and
it remained constant over doses [(F[4,23] = 1.252; p = 0.3172),
Figure 3C]. However, at the highest dose, the decrease in
MCT2 protein expression observed with CBA-shMCT2 was more
important than with the control vector and became significant
compared to the non-transduced condition (F[4,24] = 5.547;
p = 0.0028). This difference between the two vectors was clearly
visible on Western blots (Figure 3D). At the highest dose, the
downregulation with CBA-shMCT2 reached 65% compared to
the non-transduced condition. Considering the high sequence
homology between MCT2 and two other MCT isoforms, MCT1
and MCT4, the specificity of the downregulation was verified
by quantifying both MCT1 and MCT4 expression (Figure 4).
The expression levels of both MCT1 mRNA (Figure 4A) and
protein (Figure 4B) were not modified with both the shUNIV-
containing and the shMCT2-containing vectors, at all doses
tested. Representative Western blots illustrate the unchanged
MCT1 protein levels in the different conditions (Figure 4C).
The expression levels of both MCT4 mRNA (Figure 4D) and
protein (Figure 4E) were unaltered with shUNIV-containing and
shMCT2-containing vectors at all doses tested. Representative
Western blots illustrate the unchanged MCT4 protein levels
between the non-transduced condition and the highest viral dose
with both vectors (Figure 4F).
The same vectors were then injected in the S1BF area of the
rat brain. First, MCT2 mRNA levels were significantly decreased,
by 26%, after the injection of the CBA-shMCT2 viral vector
compared to the control CBA-shUNIV viral vector (Figure 3E).
The downregulation at the protein level reached 54% after the
injection of the CBA-shMCT2 viral vector (Figure 3F). The
significant decrease of MCT2 protein expression obtained after
injection of the CBA-shMCT2 viral vector was clearly visible
on representative Western blots compared to the expression
after treatment with the CBA-shUNIV viral vector (Figure 3G).
To verify the specificity of the downregulation, expression of
both MCT1 and MCT4 was quantified after the injection of
either the CBA-shUNIV or the CBA-shMCT2 viral vector. No
significant difference in MCT1 mRNA (Figure 4G) and protein
(Figure 4H) expression was detected using each of these the two
viral vectors. Representative Western blots illustrate the similar
MCT1 protein levels observed with both vectors (Figure 4I). No
significant difference in MCT4 mRNA (Figure 4J) and protein
(Figure 4K) expression was found between the two viral vectors.
Representative Western blots illustrate the lack of difference in
MCT4 protein expression following the injection of the CBA-
shUNIV and CBA-shMCT2 vectors (Figure 4L).
Downregulation of a protein involved in brain metabolism
can cause a cellular stress and be harmful for the tissue. The
presence of cell death and astrogliosis in the barrel cortex was
analyzed after the injection of each viral vector in order to detect
putative deleterious effects associated with the downregulation of
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FIGURE 2 | Large diffusion and astrocytic specificity of the AAV2/DJ-G1B3-mCherry-miR30E-shUNIV vector within the S1BF area of the rat cerebral cortex.
(A) Schematic representation of the viral vector construction used to target astrocytes. The mCherry transgene was placed under the control of a G1B3 promoter.
The shUNIV is a non-coding sequence embedded in a miR30E sequence. (B) Confocal mosaic pictures of the mCherry signal (reporter protein) after immunolabeling
of coronal brain sections taken at 20× magnification showing the diffusion of the viral vector in the cerebral cortex along the anteroposterior axis (upper panels). The
first picture was taken at bregma –1.40 mm and the last one at Bregma –3.14 mm. On the fourth picture, the position of the different cortical layers is indicated.
Scale bar = 500 µm. The lower panels represent schemes taken from the Paxinos rat atlas (Paxinos and Watson, 1996). Each of the six schemes corresponds to the
bregma level presented in the panel above. The red area corresponds to S1BF, the targeted area. (C) Representative confocal pictures of the transduced area in a
coronal brain section submitted to a co-immunolabeling for mCherry and the astrocytic marker GS. The left panel represents a mosaic picture (5 × 5 at 20×
magnification) of the transduced area in S1BF. Scale bar = 200 µm. The right picture represents a portion of the transduced area at 20× magnification. Scale
bar = 100 µm. (D) Representative confocal pictures at high magnification (40×) of S1BF 3 weeks after the injection of the viral vector and submitted to a
co-immunolabeling for mCherry, NeuN and GS. The white arrow indicates a typical transduced astrocyte. Scale bar = 50 µm. (E) Quantification of the percentage of
mCherry-positive/NeuN-positive cells and mCherry-positive/GS-positive cells. Data are presented as mean ± SEM. Quantification was performed on two to six
images per section, six sections per animal, from two animals. Statistical analysis was performed using a Student’s t-test. ∗∗∗p < 0.001.
MCT2. NeuN and GS mRNA levels were quantified to verify the
absence of neuronal and astrocytic death (Figure 4M). After the
injection of the CBA-shMCT2 vector, no significant difference
neither in the expression of the neuronal marker (NeuN) nor
in the astrocytic marker (GS) was observed compared with
the injection of the control CBA-shUNIV vector. In parallel,
the presence of astrogliosis was verified with GFAP staining
(Figure 4N). After the injection of both viral vectors, a similar
pattern of astrogliosis was observed between PBS infusion, CBA-
shUNIV and CBA-shMCT2 vectors. As expected, at the site of
the needle track, a strong astrogliosis occurred for both viral
vectors due to mechanical damage caused by the injection itself.
In non-transduced areas, no sign of astrogliosis was observed,
with low expression of GFAP and astrocytes exhibiting a normal,
non-hypertrophied shape. In transduced areas but away from
the needle track, some reactive astrocytes (i.e., GFAP-positive
and hypertrophied) were observed but with a similar occurrence
for both vectors.
Efficient Downregulation of Both
Astrocytic MCT4 mRNA and Protein
Expression in vitro as Well as in vivo
Using the Same AAV2/DJ-G1B3-
mCherry-miR30E-shMCT4 Viral
Vector
Based on the previously described vector to target astrocytes,
two viral vectors were created in order to downregulate
MCT4 expression in astrocytes. Two constructs were made
in which a shRNA sequence against MCT4 (called either
shMCT4.1 or shMCT4.2) embedded in a miR30E sequence
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FIGURE 3 | Neuronal downregulation of MCT2 expression in vitro and in vivo using an AAV2/DJ-CBA-mCherry-miR30E-shMCT2 viral vector. (A) Schematic
representation of the control (shUNIV) and shMCT2-containing constructs used to generate the neuron-specific AAV2/DJ-based viral vectors for MCT2 invalidation
experiments. The shUNIV is a non-coding sequence embedded in a miR30E sequence. The shMCT2 sequence embedded in a miR30E sequence was designed to
specifically target and downregulate rat MCT2 expression. (B–D) Impact of AAV2/DJ-CBA-shMCT2 vector on neuronal MCT2 expression in vitro. Mixed primary
cultures of rat cortical neurons and astrocytes were transduced with either the shUNIV-containing or the shMCT2-contining viral vector at increasing doses. MCT2
mRNA (B) and protein (C) levels have been determined by RT-qPCR and Western blot, respectively. Representative Western blots (D) illustrate the downregulation of
MCT2 protein expression obtained at the highest viral dose with both vectors. Data are presented as mean ± SEM. N = 3. n = 6. Statistical analysis was performed
using a one-way ANOVA followed by a Dunnett’s multiple comparison test for each viral condition. ∗p < 0.05 (compared to the non-transduced condition for each
vector). (E–G) Impact of AAV2/DJ-CBA-shMCT2 on MCT2 expression in vivo. Rats received a bilateral single injection with either the shUNIV or the shMCT2 viral
vector. MCT2 mRNA (E) and protein (F) expression have been determined by RT-qPCR and Western blot, respectively. Representative Western blots (G) illustrate
the downregulation of MCT2 protein expression with the shMCT2 viral vector vs. the shUNIV viral vector. Data are presented as mean ± SEM. N = 7. n = 2.
Statistical analysis was performed using a Student’s t-test. ∗∗∗p < 0.001. MOI, multiplicity of infection.
was placed under the control of the G1B3 promoter while
the original AAV2/DJ-G1B3-mCherry-miR30E-shUNIV
viral vector was used as control (Figure 5A). Then, mixed
primary cultures of rat cortical neurons and astrocytes
were transduced at increasing doses of each viral vector.
MCT4 mRNA expression levels decreased significantly and
proportionally to the dose using the G1B3-shMCT4.2 vector
but neither with the G1B3-shMCT4.1 vector nor with the
control G1B3-shUNIV vector (Figure 5B). At the highest dose,
the expression was decreased by 75%. The same profile of
downregulation was found at the protein level (Figure 5C).
Quantification revealed a decreased expression of the MCT4
protein proportional to the viral dose of G1B3-shMCT4.2
used, while no effect was observed with the G1B3-shMCT4.1
vector and the control G1B3-shUNIV vector. Representative
Western blots illustrate the downregulation obtained at the
highest dose, which reached 60% (Figure 5D). Considering
the high sequence homology of MCT4 with MCT1 and MCT2,
the downregulation specificity was verified by quantifying
MCT1 and MCT2 expression after transduction with each viral
vector (Figure 6). The levels of MCT1 mRNA (Figure 6A)
and protein (Figure 6B) were not significantly modified at
any dose of either G1B3-shUNIV, G1B3-shMCT4.1 or G1B3-
shMCT4.2. Representative Western blots illustrate the absence
of change in MCT1 protein expression at the highest dose
of all vectors compared to no transduction (Figure 6C). In
parallel, the levels of MCT2 mRNA (Figure 6D) and protein
(Figure 6E) were unchanged for any tested dose of each viral
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FIGURE 4 | No significant effect of the AAV2/DJ-CBA-mCherry-miR30E-shMCT2 viral vector on MCT1 and MCT4 expression as well as on cell survival or
astrogliosis. (A–C) Impact of AAV2/DJ-CBA-shMCT2 on astrocytic MCT1 expression in vitro. Mixed primary cultures of rat cortical neurons and astrocytes were
transduced with either the shUNIV-containing or the shMCT2-containing viral vector at increasing doses. MCT1 mRNA (A) and protein (B) levels have been
determined by RT-qPCR and Western blot, respectively. Representative Western blots (C) illustrate the lack of effect of both vectors on MCT1 protein expression.
Data are presented as mean ± SEM. N = 3. n = 6. Statistical analysis was performed using a one-way ANOVA for each viral condition. (D–F) Impact of
AAV2/DJ-CBA-shMCT2 on MCT4 expression in vitro. Mixed primary cultures of neurons and astrocytes were transduced with shUNIV and shMCT2 at increasing
doses. Cells were also treated with DETA-NONOate at 600 µM for 16 h to induce MCT4 expression (see section “Materials and Methods”). MCT4 mRNA (D) and
protein (E) levels have been determined by RT-qPCR and Western blot, respectively. Representative Western blots (F) illustrate the lack of effect of both vectors on
MCT4 protein expression. Data are presented as mean ± SEM. N = 3. n = 6. Statistical analysis was performed using a one-way ANOVA for each viral condition.
(G–I) Impact of AAV2/DJ-CBA-shMCT2 on MCT1 expression in vivo. Rats received a bilateral single injection with either the shUNIV or the shMCT2 viral vector.
MCT1 mRNA (G) and protein (H) levels have been determined by RT-qPCR and Western blot, respectively. Representative Western blots (I) illustrate the lack of
effect of both vectors on MCT1 protein expression in vivo. Data are presented as mean ± SEM. N = 7. n = 2. Statistical analysis was performed using a Student’s
t-test comparing shMCT2 vs. shUNIV treatment. (J–L) Impact of AAV2/DJ-CBA-shMCT2 on MCT4 expression in vivo. Rats received a bilateral single injection with
either the shUNIV or the shMCT2 viral vector. MCT4 mRNA (J) and protein (K) expression have been determined by RT-qPCR and Western blot, respectively.
Representative Western blots (L) illustrate the lack of effect of both vectors on MCT4 protein expression in vivo. Data are represented as mean ± SEM. N = 7. n = 2.
Statistical analysis was performed using a Student’s t-test comparing shMCT2 vs. shUNIV treatment. (M) Evaluation of neuronal and astrocytic cell death after
injection of AAV2/DJ-CBA-shMCT2 in the S1BF area by measuring NeuN and GS mRNA expression. Statistical analysis was performed using a Student’s t-test
comparing shMCT2 vs. shUNIV treatment. (N) Representative confocal images of immunolabeling performed against GFAP on brain coronal sections to detect
astrogliosis following the injection of PBS, AAV2/DJ-CBA-shUNIV or AAV2/DJ-CBA-shMCT2 in the S1BF area. Scale bar = 50 µm. MOI, Multiplicity of infection.
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FIGURE 5 | Astrocytic downregulation of MCT4 expression in vitro and in vivo using AAV2/DJ-G1B3-mCherry-miR30E-shMCT4 viral vectors. (A) Schematic
representation of the control (shUNIV) and two shMCT4-containing constructs used to generate the astrocyte-specific AAV2/DJ-based viral vectors for MCT4
invalidation experiments. The shUNIV is a non-coding sequence embedded in a miR30E sequence. The two shMCT4 embedded in a miR30E sequence were
designed to specifically target and downregulate rat MCT4 expression. (B–D) Impact of AAV2/DJ-G1B3-shMCT4 vectors on astrocytic MCT4 expression in vitro.
Mixed primary cultures of rat cortical neurons and astrocytes were transduced with either the shUNIV-containing, the shMCT4.1-containing or the
shMCT4.2-containing vectors at increasing doses. Cells were treated with DETA-NONOate at 600 µM for 16 h to induce MCT4 expression (see section “Materials
and Methods”). MCT4 mRNA (B) and protein (C) expression have been determined by RT-qPCR and Western blot, respectively. Representative Western blots (D)
illustrate the downregulation of MCT4 protein expression obtained with the shMCT4.2-containing vector vs. the shUNIV-containing and shMCT4.1 vectors. Data are
presented as mean ± SEM. N = 3. n = 6. Statistical analysis was performed using a one-way ANOVA followed by a Dunnett’s multiple comparison test for each viral
condition. ∗p < 0.05 (compared to the non-transduced condition for each vector). (E–G) Impact of AAV2/DJ-G1B3-shMCT4 on MCT4 expression in vivo. Rats
received a single injection in each S1BF area with either shUNIV-containing or shMCT4.2-containing (called shMCT4) viral vector at a single dose. MCT4 mRNA (E)
and protein (F) levels have been determined by RT-qPCR and Western blot, respectively. Representative Western blots (G) illustrate the downregulation of MCT4
protein expression with the shMCT4 viral vector vs. the shUNIV viral vector. Data are presented as mean ± SEM. N = 7. n = 2. Statistical analysis was performed
using a Student’s t-test. ∗p < 0.05; ∗∗p < 0.01. MOI, Multiplicity of infection.
vector. Representative Western blots illustrate the absence of
modification of MCT2 protein expression with either G1B3-
shUNIV, G1B3-shMCT4.1, or G1B3-shMCT4.2 at the highest
dose (Figure 6F).
The control vector (G1B3-shUNIV) and the shMCT4-
containing vector showing in vitro efficiency in downregulating
MCT4 (G1B3-shMCT4.2) were then injected at a single site in
the S1BF area of the rat brain (same stereotaxic coordinates as
previously indicated). It was found that MCT4 mRNA expression
was significantly decreased, by 34%, after the injection of the
G1B3-shMCT4.2 vector compared to the shUNIV-containing
control vector (Figure 5E). Downregulation of the MCT4
protein reached 67% after the injection of the G1B3-shMCT4.2
vector compared to the shUNIV-containing control (Figure 5F).
Representative Western blots illustrate the significant decrease of
MCT4 protein expression obtained in the S1BF area of the rat
brain (Figure 5G). To verify the specificity of the downregulation
obtained in vivo, MCT1 and MCT2 expression levels were also
quantified after the injection of the G1B3-shMCT4.2 viral vector
in the S1BF area. The levels of MCT1 mRNA (Figure 6G) and
protein (Figure 6H) were not significantly different between
the two viral vectors. Representative Western blots illustrate the
absence of modification of MCT1 protein levels between both
vectors (Figure 6I). Concerning MCT2, it’s mRNA (Figure 6J)
and protein (Figure 6K) expression did not differ between G1B3-
shMCT4.2 and G1B3-shUNIV vectors. Representative Western
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FIGURE 6 | No significant effect of the AAV2/DJ-G1B3-mCherry-miR30E-shMCT4.1 and the AAV2/DJ-G1B3-mCherry-miR30E-shMCT4.2 viral vectors on MCT1
and MCT2 expression as well as on cell survival or astrogliosis. (A–C) Impact of AAV2/DJ-G1B3-shMCT4.1 and AAV2/DJ-G1B3-shMCT4.2 on astrocytic MCT1
expression in vitro. Mixed primary cultures of rat cortical neurons and astrocytes were transduced with either the shUNIV-containing, the shMCT4.1-containing or the
shMCT4.2-containing viral vector at increasing doses. MCT1 mRNA (A) and protein (B) expression have been determined by RT-qPCR and Western blot,
respectively. Representative Western blots (C) illustrate the lack of effect of the three vectors on astrocytic MCT1 protein expression. Data are presented as
mean ± SEM. N = 3. n = 6. Statistical analysis was performed using a one-way ANOVA for each viral condition. (D–F) Impact of AAV2/DJ-G1B3-shMCT4.1 and
AAV2/DJ-G1B3-shMCT4.2 on MCT1 expression in vitro. Mixed primary cultures of rat cortical neurons and astrocytes were transduced with either the
shUNIV-containing, the shMCT4.1-containing or the shMCT4.2-containing viral vector at increasing doses. MCT2 mRNA (D) and protein (E) levels have been
determined by RT-qPCR and Western blot, respectively. Representative Western blots (F) illustrate the lack of effect of the three vectors on neuronal MCT2 protein
expression. Data are presented as mean ± SEM. N = 3. n = 6. Statistical analysis was performed using a one-way ANOVA for each viral condition. (G–I) Impact of
AAV2/DJ-G1B3-shMCT4.2 on MCT1 expression in vivo. Rats received a single injection in each S1BF area with either the shUNIV-containing or the
shMCT4.2-containing viral vector at a single dose. MCT1 mRNA (G) and protein (H) expression have been determined by RT-qPCR and Western blot, respectively.
Representative Western blots (I) illustrate the lack of effect of both vectors on MCT1 protein expression in vivo. Data are presented as mean ± SEM. N = 7. n = 2.
Statistical analysis was performed using a Student’s t-test comparing shMCT4.2 vs. shUNIV treatment. (J–L) Impact of AAV2/DJ-G1B3-shMCT4.2 on MCT2
expression in vivo. Rats received a bilateral single injection with either the shUNIV-containing or the shMCT4.2-containing viral vector. MCT2 mRNA (J) and protein
(K) expression have been determined by RT-qPCR and Western blot, respectively. Representative Western blots (L) illustrate the lack of effect of both vectors on
MCT2 protein expression in vivo. Data are presented as mean ± SEM. N = 7. n = 2. Statistical analysis was performed using a Student’s t-test comparing
treatments. (M) Evaluation of neuronal and astrocyte cell death after injection of AAV2/DJ-G1B3-shMCT4.2 in the S1BF area by measuring NeuN and GS mRNA
expression. Statistical analysis was performed using a Student’s t-test comparing shMCT4.2 vs. shUNIV treatment. (N) Representative confocal images of
immunolabeling performed against GFAP on brain coronal sections to detect astrogliosis following the injection of PBS, AAV2/DJ-G1B3-shUNIV or
AAV2/DJ-G1B3-shMCT4.2 in the S1BF area. Scale bar = 50 µm. MOI, Multiplicity of infection.
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blots illustrate this lack of difference in MCT2 protein expression
between the two vectors (Figure 6L).
Cell death and astrogliosis in the S1BF area were analyzed
after the injection of either the G1B3-shMCT4.2 or the control
G1B3-shUNIV viral vector. NeuN and GS mRNA levels were
quantified to verify the absence of neuronal and astrocytic
death, respectively (Figure 6M). No sign of neuronal death, as
indicated by equivalent NeuN mRNA levels, or astrocytic death,
indicated by equivalent GS mRNA levels, was observed when
comparing the effect of both vectors. The presence of astrogliosis
was evaluated using GFAP immunolabeling on coronal sections
of the brain (Figure 6N). A similar pattern of astrogliosis
was observed between PBS infusion, G1B3-shUNIV, and G1B3-
shMCT4 vectors. In non-transduced areas, no astrogliosis was
observed with low expression of GFAP and normal astrocytic
shape. In transduced areas but away from the needle track,
some reactive astrocytes were observed but their number did
not differ between the two conditions. As expected at the site of
the needle track, a strong astrogliosis occurred but to a similar
extent for both viral vectors due to mechanical damage caused
by the injection.
DISCUSSION
The initial goal of this study was to develop viral vectors to
alternatively target two cell types by using the same capsid
while modifying only the promoter of the construct. The two
cell types chosen as targets were rat cortical neurons and
astrocytes. Usually, viral vectors derived from either lenti- or
adeno-associated viruses exhibit a preferential tropism toward
either neurons or astrocytes (Wu et al., 2006; Aschauer et al.,
2013). The AAV6 has already been used to selectively transduce
astrocytes both in vitro and in vivo (Schober et al., 2016).
However, in this study the authors used another serotype to
target neurons (AAV2). Because our goal was to alternatively
target a specific cell type with the same serotype, we selected the
AAV2/DJ viral capsid as it was shown to efficiently transduce
different cell types and cell lines (Grimm et al., 2008). Concerning
the promoters, it was previously shown that the CBA promoter
exhibits a neuronal specificity for expression in the brain (Burger
et al., 2004; von Jonquieres et al., 2013; Meunier et al., 2016). We
showed here that, in combination with an AAV2/DJ backbone, it
conserved its neuronal specificity both in vitro and in vivo. The
astrocytic promoter G1B3 has been shown to confer astrocyte
specificity of expression in the mouse striatum (Merienne et al.,
2017). Indeed, in combination with the AAV2/5, it was found to
drive the expression of a transgene predominantly in astrocytes
in vivo. The possibility to use the same viral vector to target
two different cell types of the same tissue both in vitro and
in vivo presents several advantages. Up to now, the use of AAV-
based vectors prevented this possibility since the efficiency of
infection of most AAV serotypes in vitro was very low (Ellis
et al., 2013). It is not the case with the AAV2/DJ that permitted
a significant transduction of primary cultures of both rat cortical
neurons and astrocytes. It was thus possible to test in vitro the
efficiency of our selected shRNA sequences in downregulating
the expression of the target mRNAs and proteins prior to use
them in vivo. Moreover, this approach allows to reduce the
number of animals needed to assess the usefulness of such
newly developed molecular tools, respecting the 3R principles
(MacArthur Clarke, 2018).
In addition to their efficiency in vitro, the AAV2/DJ-
based viral vectors were capable to efficiently transduce both
neurons and astrocytes in vivo as demonstrated in the rat
somatosensory cortex. Despite this convincing demonstration in
the somatosensory cortex, it remains to be examined whether
this efficiency could vary in different brain regions as previously
reported for other AAV serotypes (Aschauer et al., 2013). In
addition, it might be interesting to verify if this approach could
be extended to other brain cell types such as oligodendrocytes
or microglial cells. Although specific promoters for each of
these cell types have already been identified (Goldmann et al.,
2013; Georgiou et al., 2017), few AAV-based vectors have
been developed to target them both in vitro and in vivo.
Oligodendrocytes could be transduced in vivo with an AAV-
based vector but it was not tested in vitro (von Jonquieres et al.,
2013). The transduction of microglial cells in vitro has been
reported using a modified AAV6 capsid and microglial-specific
promoters but the transduction was low in vivo (Rosario et al.,
2016). The use of the AAV2/DJ might be of interest to successfully
transduce microglia and oligodendrocytes both in vitro and
in vivo. Another important aspect concerns the capacity of viral
vectors to diffuse over a large tissue area. Indeed, we found that
AAV2/DJ-based viral vectors exhibited an important spreading
capacity, sufficient to cover an area representing more than half
of the entire barrel cortex with a single injection. Moreover,
AAV2/DJ-based viral vectors efficiently diffused not only laterally
but also throughout the cortical thickness, reaching all six cortical
layers. This is also an appreciable feature since it is possible to
avoid making several injections at different locations to cover
the targeted area, reducing the degree of potential damage to
the tissue. Interestingly, a difference in the diffusion pattern
of the fluorescent signal between CBA-based and G1B3-based
vectors was observed. It was recently shown that astrocytes
were poorly covered by 2D imaging. Less than 10% of their
true volume seemed to be covered by 2D imaging (Bindocci
et al., 2017). Indeed, the soma represents only 25% of the total
astrocytic volume. The diameter of a process being fine and
processes being sparse, a large proportion of the processes are
not captured in the focal plan. Moreover, even with the best
confocal microscope, processes, and endfeet cannot be clearly
seen because of resolution limitations. So, the total volume of
astrocytic transduction might be underestimated although the
percentage of transduced astrocytes would likely remain the
same. Despite these caveats, it seems that both viral vector
types based on AAV2/DJ to target alternatively neurons and
astrocytes allow to express a transgene in a predominantly cell-
specific manner and with a large diffusion within a brain cortical
region of interest.
These new tools might be particularly useful to investigate
a physiologically relevant question requiring to target the same
protein or two closely related proteins in two distinct brain cell
types. This is the case for two isoforms of the MCT protein
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family: MCT2 and MCT4. MCT2 is specifically expressed in
neurons while MCT4 is exclusively expressed by astrocytes in
the cortex (Pierre and Pellerin, 2005). Both transporters have
been implicated in a mechanism of lactate transfer between
the two cell types to ensure an adequate energy substrate
supply to neurons as a function of brain activity (Pellerin and
Magistretti, 2012). In order to get further insight about the role
of these transporters in this mechanism, it became necessary
to develop efficient and specific viral vectors to downregulate
the expression of those two isoforms in rat, because working
with rats rather than mice represent an advantage in certain
circumstances (e.g., perform brain imaging). Using the same AAV
serotype in vitro and in vivo, we show here that a significant
and specific decrease in expression could be obtained for both
MCT2 and MCT4. A variance of distribution is observed for
the mRNA and protein quantifications. It can be explained
by several reasons. First, for the in vitro results, the graphs
summarize quantifications from several primary cultures. Even
if the basal level of each mRNA/protein could differ between
cultures, the degree of down regulation after transduction is the
same in every culture. Then, even if the same number of cells
is plated, the same dose of viral vector is given (in vitro as
in vitro), leading to a certain unavoidable variability. Moreover,
this downregulation was specific of the targeted isoform, since
the expression of other isoforms remained unchanged. Because
of technical issues related to the sampled area of tissue that
cannot be limited to the transduced area and the number of
infected cells that is not 100%, the degree of downregulation
is underestimated in vivo. The use of cell sorting to isolate
only transduced cells would be required to have a more precise
assessment of the downregulation. Nevertheless, a significant
downregulation of MCT2 and MCT4 using AAV-based viral
vectors could be evidenced directly from large punches of
tissue. It represents an improvement over the previous use of
a classical shRNA sequence in a lentiviral vector that led to a
slight decrease of the expression of MCT2 in a small fraction
of cortical neurons only detectable by immunocytochemistry
at the protein level (Mazuel et al., 2017). Considering that,
despite the smaller decrease in MCT2 protein expression
detected previously, functional effects (notably on the BOLD
fMRI response during whisker stimulation) were evidenced
with the lentiviral-based vector (Mazuel et al., 2017), it is
likely that the new AAV-based vectors should provide more
efficient tools to explore the importance of MCTs in specific
brain functions.
Apart from their higher degree of transduction efficiency, and
considering the high sequence homology between the different
MCTs (Halestrap, 2013), the cell specificity of each AAV-based
viral vector for each MCT in each cell type is another advantage.
Indeed, the use of a miR30 backbone and cell-specific promoters
proved to be sufficient to obtain such a specificity.
Another important issue was the possible toxicity of the AAV-
based vectors. Indeed, at high doses, viral vectors can cause cell
death (Colella et al., 2018; Hinderer et al., 2018). Moreover,
strong and uncontrolled shRNA expression could contribute to
toxicity. Although cultured astrocytes showed no sign of toxicity
for the range of doses tested, we noticed that low doses of
AAV2/DJ-based viral vectors caused a partial decrease of MCT2
protein expression that does not seem related to cell death
of cultured neurons (since actin expression remained constant
between conditions). This effect was not dose-dependent over
the range of doses tested and was independent of the transgene.
Although the precise reason for this effect is uncertain, primary
cultures of neurons are notoriously known to be sensitive to
various stressors (Fricker et al., 2018). For example, it was
shown that B27-supplement deprivation of cultured cortical
neurons leads to partial neuronal cell death (Alvarez-Flores et al.,
2019). Cultured neurons might also be particularly sensitive
to mCherry overexpression, independently of the serotype.
Indeed, expression of the fluorescent reporter protein GFP has
been reported to cause toxicity (Liu et al., 1999) and even
neuronal death (Detrait et al., 2002). The doses that we used
are considered as classical for in vitro transduction (Gong et al.,
2004; Shevtsova et al., 2004) but cultured neurons seem to
be particularly sensitive to viral vector transduction as they
modify their transcriptome (Préhaud et al., 2005) or die by
apoptosis (Howard et al., 2008). In our case, it seems that neurons
reacted to viral transduction by modifying their proteome and
decreasing MCT2. This could reflect a modification of their
metabolism. Nevertheless, it was still possible in cultured neurons
to unravel a significant downregulating effect of the transgene at
the highest viral vector dose used. The use of a miR30E backbone
for the shRNA sequence may have contributed to the absence
of cell death. Indeed, it was shown that the addition of this
backbone allows the cell to process the shRNA sequence through
the endogenous miR30 pathways, which decreases toxicity
(Boudreau et al., 2009). Consequently, it can be concluded that
the observed decrease in MCT2/MCT4 expression in vivo is
entirely due to the specific action of the shRNA sequence on
the targeted mRNA.
In parallel, the reactive state of the astrocytes in the transduced
area was also verified. Indeed, astrogliosis is a protective
mechanism of the brain in case of CNS injuries (Sofroniew, 2015).
This natural process can become deleterious when the injury
or the inflammation is too high. In addition, an uncontrolled
astrogliosis can alter the function of neighboring cells. An
important astrogliosis just around the needle track was observed
while a moderate to low astrogliosis was found in the transduced
area. The astrogliosis around the needle track is essentially due
to the mechanical damages caused by the needle and the liquid
flow. The same degree of astrogliosis was found between PBS
and the different viral vectors, highlighting the mechanical cause
of this astrogliosis. In the transduced area, it could not be
excluded that astrogliosis could contribute to counterbalance
the downregulation of MCT4 observed with the shMCT4, thus
partly masking the effective degree of MCT4 downregulation.
Indeed, it was previously shown that reactive astrocytes become
more glycolytic (Iglesias et al., 2017) and thus could express
more MCT4, as it was shown for astrocytes in vitro submitted
to hypoxia (Rosafio and Pellerin, 2014) or in vivo after ischemia
(Rosafio et al., 2016).
In conclusion, unique viral tools have been successfully
created that largely diffuse in the somatosensory cortex and
that can specifically target neurons or astrocytes depending on
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the promoter used. Moreover, associated to a miR30E-shRNA
strategy, an isoform-specific downregulation could be obtained
with no sign of toxicity in vivo. In the present study, these
tools have been used to target two isoforms of the MCT family,
MCT2, and MCT4. Such tools will be particularly useful to study
the precise role of MCTs in brain energy metabolism and brain
functions in vivo, especially for aspects for which invalidation in
rats represents an advantage over the use of transgenic mice. Until
now, several studies have been conducted using pharmacological
antagonists (Dimmer et al., 2000; Colen et al., 2006). To inhibit
MCTs, CHC [2-Cyano-3-(4-hydroxyphenyl)-2-propenoic acid]
has been widely used. However, CHC also targets other proteins
such as the mitochondrial pyruvate carrier (Gray et al., 2015).
To circumvent this problem, RNA interference has been used
in the past (Maekawa et al., 2008; Suzuki et al., 2011), and
later it was associated with a viral vector approach for an
in vivo use. Recently, functional effects of the downregulation
of MCT2 in vivo were detected using a lentiviral approach
targeting MCT2 (Mazuel et al., 2017). However, the extent
of the downregulation was limited and might preclude more
complex investigations such as behavioral studies. Our new
AAV-based viral vectors will not only allow to overcome these
caveats but they could also be used in the future to target other
proteins of interest in the central nervous system requiring a
similar strategy.
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